Can we Predict COronary Resistance By EYE Examination ? (COREYE)

Sponsor
Hospices Civils de Lyon (Other)
Overall Status
Recruiting
CT.gov ID
NCT03739073
Collaborator
(none)
210
1
1
66
3.2

Study Details

Study Description

Brief Summary

Prospective interventional study, open, non-comparative and non-randomized. The research concerns physiological parameters of the coronary and ocular blood circulation.

At the coronary level, the curves of pressure and Doppler flow will be extracted from ComboMap® (Philips). The coronary microvascular resistances, basal and hyperemic, will be determined by the average ratio of the distal pressure and flow.

At the ocular level, a fundus oculi and an OCTA (angiography by tomography in optical coherence) examination will be performed. The measures of the FFR and the coronary microvascular resistance will be determined by a specific guidewire allowing simultaneous measures of pressure and Doppler flow (ComboWire®, Philips), in 200 patients with intermediate stenosis of the left anterior descending artery (LDA). Topological parameters characterizing the retinal area and choriocapillaries will be determined by statistical approaches and mathematical morphology.

To establish a predictor of the coronary microvascular resistance from the eye vascular parameters, we shall use a non-linear regression by supervised machine learning. The main cardiovascular risk factors (hypertension, diabetes, dyslipidemia, age, sex) will be part of predetermined input features for the machine learning.

Condition or Disease Intervention/Treatment Phase
  • Other: OCTA (angiography by tomography in optical coherence)
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
210 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Can we Predict COronary Resistance By EYE Examination ?
Actual Study Start Date :
Oct 4, 2018
Anticipated Primary Completion Date :
Apr 4, 2024
Anticipated Study Completion Date :
Apr 4, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Patient with coronary arterial indication

A fundus oculi and an OCTA (angiography by tomography in optical coherence) examination will be performed for patients with intermediate stenosis of the left anterior descending artery (LDA).

Other: OCTA (angiography by tomography in optical coherence)
The study concerns patients with intermediate stenosis of the left anterior descending artery (LDA). A fundus oculi and an OCTA (angiography by tomography in optical coherence) examination will be performed; it's a non-invasive imaging test. OCT uses light waves to take cross-section pictures of your retina and then ophthalmological examination data will correlate with coronary angiography.

Outcome Measures

Primary Outcome Measures

  1. Coronary microvascular resistance results (Combowire) [Day 1]

    Estimed by Combowire During coronary angiography, coronary resistance will be measured by pressure and Doppler guides in patients with intermediate coronary stenosis according to the usual procedure. Correlation between results of Combowire® coronary microvascular resistance and OCTA ophthalmologic findings. A machine learning technique will be used to analyze this series of ocular data and to determine a predictor of post-treatment coronary microvascular resistance.

  2. Coronary microvascular resistance results (OCTA) [Day 1]

    Estimated by ophthalmological examinations data from OCTA. An examination of fundus of the eye will then be performed by optical coherence tomography angiography without injection PLEX Elite 9000. Correlation between results of Combowire® coronary microvascular resistance and OCTA ophthalmologic findings. A machine learning technique will be used to analyze this series of ocular data and to determine a predictor of post-treatment coronary microvascular resistance.

Secondary Outcome Measures

  1. angiographical stenosis [Day 1]

    measurement will be determined by specific guide allowing simultaneous measurements of pressure and spectral Doppler (Combowire®)

  2. Fractional Flow Reserve (FFR) [Day 1]

    measurement of FFR will be determined by specific guide allowing simultaneous measurements of pressure and spectral Doppler (Combowire®)

  3. coronary microvascular resistance (CFR) [Day 1]

    measurement of CFR will be determined by specific guide allowing simultaneous measurements of pressure and spectral Doppler (Combowire®)

  4. microvascular resistance values [Year 1]

    Microvascular resistances will be measured using (Combowire®). The values of these resistances will be compared between the patient groups according to their cardiovascular risk factor

  5. total area of flow signal void on the choriocapillaris layer [Year 1]

    The total area of flow signal void on the choriocapillaris layer will be calculated with help of MATLAB software and will be correlated with cardiovascular risk-factors

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Male and female patient's ≥18 years of age with coronary arterial indication as usual and with proximal and / or mean IVA stenosis ≥ 50%.

  2. Signed informed consent

  3. Affiliation to the social security system

Exclusion Criteria:
  1. Unstable Coronary Artery Disease

  2. Atrial fibrillation

  3. History of myocardial infarction <6 months in the territory of the proximal and / or mean IVA.

  4. Asthma

  5. Aortocoronary bypass surgery.

  6. Collateral development at the level of the proximal and / or mean IVA.

  7. Allergy to iodine, severe renal insufficiency.

  8. Ametropia> = 6 diopters.

  9. History of retinal ocular pathologies other than uncomplicated diabetic retinopathy and hypertensive retinopathy.

  10. History of ophthalmic treatments such as macular or panretinal laser photocoagulation, intravitreal injection of anti-VEGF or cortisone.

  11. Chronic glaucoma

  12. Patients under guardianship or curators.

  13. Pregnant or lactating women.

  14. Patient's not affiliated to the French social security.

  15. Persons placed under the protection of justice,

  16. Subject participating in another research including an exclusion period still in progress at pre-inclusion

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospices Civils de Lyon - Hopital de la Croix Rousse Lyon France 69004

Sponsors and Collaborators

  • Hospices Civils de Lyon

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hospices Civils de Lyon
ClinicalTrials.gov Identifier:
NCT03739073
Other Study ID Numbers:
  • 69HCL18_0301
  • 2018-A01181-54
First Posted:
Nov 13, 2018
Last Update Posted:
Jan 11, 2022
Last Verified:
Dec 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 11, 2022